Cita APA

Le Tourneau, C., Becker, H., Claus, R., Ricci, F., Fritsch, R., Elez, E., & Tabernero, J. (2022). Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors.

Citación estilo Chicago

Le Tourneau, Christophe, Heiko Becker, Rainer Claus, Francesco Ricci, R. Fritsch, Elena Elez, y Josep Tabernero. Two Phase I Studies of BI 836880, a Vascular Endothelial Growth Factor/angiopoietin-2 Inhibitor, Administered Once Every 3 Weeks or Once Weekly in Patients With Advanced Solid Tumors. 2022.

Cita MLA

Le Tourneau, Christophe, et al. Two Phase I Studies of BI 836880, a Vascular Endothelial Growth Factor/angiopoietin-2 Inhibitor, Administered Once Every 3 Weeks or Once Weekly in Patients With Advanced Solid Tumors. 2022.